找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller Book 2016Latest edition Springer International Publishing Switzerlan

[復制鏈接]
樓主: 厭倦了我
41#
發(fā)表于 2025-3-28 16:02:43 | 只看該作者
Margareta Stefanovic,Michael G. Safonovand that “drug therapy varies widely among individuals” [.]. These two statements set the stage for the discipline of clinical pharmacology (CP) which pursues two main goals: (1) an empirical description of conditions under which drug actions vary in humans and (2) to determine and understand the mo
42#
發(fā)表于 2025-3-28 20:33:58 | 只看該作者
Margareta Stefanovic,Michael G. Safonoves, most notably infections, have extremely satisfying therapeutic success rates, and many serious diseases like diabetes mellitus or some forms of cancer have become chronic, stable diseases and do not lead to extreme shortages of life years any longer. Prime examples for success stories in drug de
43#
發(fā)表于 2025-3-29 00:38:09 | 只看該作者
44#
發(fā)表于 2025-3-29 04:27:29 | 只看該作者
45#
發(fā)表于 2025-3-29 09:45:47 | 只看該作者
46#
發(fā)表于 2025-3-29 14:01:19 | 只看該作者
Ken Chan,Clive Fencott,Barry Hebbronessively establish their safety and ultimately their efficacy. Disasters occur only rarely during phase I trials, which have a remarkable safety record. In 2006, a contract research organization was conducting the first human testing of TGN1412 an immunomodulatory anti-CD28 monoclonal antibody. All
47#
發(fā)表于 2025-3-29 19:36:42 | 只看該作者
48#
發(fā)表于 2025-3-29 20:30:31 | 只看該作者
49#
發(fā)表于 2025-3-30 03:06:15 | 只看該作者
50#
發(fā)表于 2025-3-30 07:34:57 | 只看該作者
Legal Aspects of Safety Critical Systemse the number of compounds where the pharmacokinetics observed at a microdose compared to a therapeutic dose has grown steadily. Based upon the most up-to-date review at the time of writing (2013, reference Lappin et al., Expert Opin Drug Metab Toxicol 9(7):817–834, 2013), there are 35 compounds wher
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 23:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
泰宁县| 东兴市| 曲阜市| 鄂州市| 鹤庆县| 元阳县| 林西县| 海伦市| 临泽县| 辉南县| 丹江口市| 惠东县| 柘城县| 商洛市| 大竹县| 出国| 余姚市| 宾阳县| 罗源县| 云林县| 清流县| 黄大仙区| 遂川县| 英吉沙县| 理塘县| 江都市| 临江市| 深圳市| 开远市| 武陟县| 亚东县| 正蓝旗| 分宜县| 获嘉县| 荥阳市| 长宁县| 建水县| 荆州市| 安达市| 怀安县| 黑龙江省|